Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models

Inés García-Rodríguez; Giulia Moreni; Pamela E Capendale; Lance Mulder; Ikrame Aknouch; Renata Vieira de Sá; Nina Johannesson; Eline Freeze; Hetty van Eijk; Gerrit Koen; Katja C Wolthers; Dasja Pajkrt; Adithya Sridhar; Carlemi Calitz

doi:10.1016/j.antiviral.2024.105798

Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models

Emma Children's Hospital
Department of Pediatric Infectious Diseases, Amsterdam, Netherlands
Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, location Academic Medical Center, Amsterdam, the Netherlands.
Center for Reproductive Medicine, Amsterdam Reproduction and Development Institute, Academic Medical Centre, Amsterdam, The Netherlands.
University of Amsterdam
OrganoVIR Labs
Department of Medical Microbiology
Viroclinics Xplore
uniQure

Research output: Contribution to journal › Article › Academic › peer-review

28 Downloads (Pure)

Abstract

Halofuginone hydrobromide has shown potent antiviral efficacy against a variety of viruses such as SARS-CoV-2, dengue, or chikungunya virus, and has, therefore, been hypothesized to have broad-spectrum antiviral activity. In this paper, we tested this broad-spectrum antiviral activity of Halofuginone hydrobomide against viruses from different families (Picornaviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, and Flaviviridae). To this end, we used relevant human models of the airway and intestinal epithelium and regionalized neural organoids. Halofuginone hydrobomide showed antiviral activity against SARS-CoV-2 in the airway epithelium with no toxicity at equivalent concentrations used in human clinical trials but not against any of the other tested viruses.

Original language	English
Article number	105798
Pages (from-to)	105798
Journal	Antiviral research
Volume	222
DOIs	https://doi.org/10.1016/j.antiviral.2024.105798
Publication status	Published - 1 Feb 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Antiviral Agents/pharmacology
Microphysiological Systems
Viruses
SARS-CoV-2
Brain
Piperidines
Quinazolinones
Antiviral
EV-A71
HAE
HCMV
HIE
Halofuginone
Influenza A
PeV-A1
Rhinovirus
Zika

Access to Document

10.1016/j.antiviral.2024.105798

Assessment-of-the-broad-spectrum-host-targeting-antiviral-efficacy-of-halofuginone-hydrobromide-in-human-airway-intesti.pdfFinal published version, 5.67 MBLicence: CC BY

Cite this

García-Rodríguez, I., Moreni, G., Capendale, P. E., Mulder, L., Aknouch, I., Vieira de Sá, R., Johannesson, N., Freeze, E., van Eijk, H., Koen, G., Wolthers, K. C., Pajkrt, D., Sridhar, A., & Calitz, C. (2024). Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models. Antiviral research, 222, 105798. Article 105798. https://doi.org/10.1016/j.antiviral.2024.105798

@article{93ee88cdc5ba43e083fd8abf7a1c21b9,

title = "Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models",

abstract = "Halofuginone hydrobromide has shown potent antiviral efficacy against a variety of viruses such as SARS-CoV-2, dengue, or chikungunya virus, and has, therefore, been hypothesized to have broad-spectrum antiviral activity. In this paper, we tested this broad-spectrum antiviral activity of Halofuginone hydrobomide against viruses from different families (Picornaviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, and Flaviviridae). To this end, we used relevant human models of the airway and intestinal epithelium and regionalized neural organoids. Halofuginone hydrobomide showed antiviral activity against SARS-CoV-2 in the airway epithelium with no toxicity at equivalent concentrations used in human clinical trials but not against any of the other tested viruses.",

keywords = "Humans, Antiviral Agents/pharmacology, Microphysiological Systems, Viruses, SARS-CoV-2, Brain, Piperidines, Quinazolinones, Antiviral, EV-A71, HAE, HCMV, HIE, Halofuginone, Influenza A, PeV-A1, Rhinovirus, Zika",

author = "In{\'e}s Garc{\'i}a-Rodr{\'i}guez and Giulia Moreni and Capendale, \{Pamela E\} and Lance Mulder and Ikrame Aknouch and \{Vieira de S{\'a}\}, Renata and Nina Johannesson and Eline Freeze and \{van Eijk\}, Hetty and Gerrit Koen and Wolthers, \{Katja C\} and Dasja Pajkrt and Adithya Sridhar and Carlemi Calitz",

year = "2024",

month = feb,

day = "1",

doi = "10.1016/j.antiviral.2024.105798",

language = "English",

volume = "222",

pages = "105798",

journal = "Antiviral research",

issn = "0166-3542",

publisher = "Elsevier",

}

García-Rodríguez, I , Moreni, G , Capendale, PE , Mulder, L, Aknouch, I, Vieira de Sá, R, Johannesson, N , Freeze, E, van Eijk, H, Koen, G, Wolthers, KC , Pajkrt, D , Sridhar, A & Calitz, C 2024, 'Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models', Antiviral research, vol. 222, 105798, pp. 105798. https://doi.org/10.1016/j.antiviral.2024.105798

Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models. / García-Rodríguez, Inés ; Moreni, Giulia ; Capendale, Pamela E et al.
In: Antiviral research, Vol. 222, 105798, 01.02.2024, p. 105798.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models

AU - García-Rodríguez, Inés

AU - Moreni, Giulia

AU - Capendale, Pamela E

AU - Mulder, Lance

AU - Aknouch, Ikrame

AU - Vieira de Sá, Renata

AU - Johannesson, Nina

AU - Freeze, Eline

AU - van Eijk, Hetty

AU - Koen, Gerrit

AU - Wolthers, Katja C

AU - Pajkrt, Dasja

AU - Sridhar, Adithya

AU - Calitz, Carlemi

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Halofuginone hydrobromide has shown potent antiviral efficacy against a variety of viruses such as SARS-CoV-2, dengue, or chikungunya virus, and has, therefore, been hypothesized to have broad-spectrum antiviral activity. In this paper, we tested this broad-spectrum antiviral activity of Halofuginone hydrobomide against viruses from different families (Picornaviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, and Flaviviridae). To this end, we used relevant human models of the airway and intestinal epithelium and regionalized neural organoids. Halofuginone hydrobomide showed antiviral activity against SARS-CoV-2 in the airway epithelium with no toxicity at equivalent concentrations used in human clinical trials but not against any of the other tested viruses.

AB - Halofuginone hydrobromide has shown potent antiviral efficacy against a variety of viruses such as SARS-CoV-2, dengue, or chikungunya virus, and has, therefore, been hypothesized to have broad-spectrum antiviral activity. In this paper, we tested this broad-spectrum antiviral activity of Halofuginone hydrobomide against viruses from different families (Picornaviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, and Flaviviridae). To this end, we used relevant human models of the airway and intestinal epithelium and regionalized neural organoids. Halofuginone hydrobomide showed antiviral activity against SARS-CoV-2 in the airway epithelium with no toxicity at equivalent concentrations used in human clinical trials but not against any of the other tested viruses.

KW - Humans

KW - Antiviral Agents/pharmacology

KW - Microphysiological Systems

KW - Viruses

KW - SARS-CoV-2

KW - Brain

KW - Piperidines

KW - Quinazolinones

KW - Antiviral

KW - EV-A71

KW - HAE

KW - HCMV

KW - HIE

KW - Halofuginone

KW - Influenza A

KW - PeV-A1

KW - Rhinovirus

KW - Zika

UR - https://www.scopus.com/pages/publications/85183555948

U2 - 10.1016/j.antiviral.2024.105798

DO - 10.1016/j.antiviral.2024.105798

M3 - Article

C2 - 38190972

SN - 0166-3542

VL - 222

SP - 105798

JO - Antiviral research

JF - Antiviral research

M1 - 105798

ER -

Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this